InteRNA and Silence to develop microRNA cancer therapeutics
This article was originally published in Scrip
Executive Summary
Dutch company InteRNA Technologies has entered into an agreement with Silence Therapeutics to develop new microRNA drugs in oncology. The collaboration will look to using Silence's AtuPLEX delivery system in combination with InteRNA's microRNA therapeutics.